Incyte Corp. Stock
Incyte Corp. Stock
Incyte Corp. gained 0.820% compared to yesterday.
We see a rather positive sentiment for Incyte Corp. with 10 Buy predictions and 2 Sell predictions.
With a target price of 78 € there is a hugely positive potential of 61.52% for Incyte Corp. compared to the current price of 48.29 €.
Our community identified positive and negative aspects for Incyte Corp. stock for the coming years. 1 users see the criterium "EBIT growth" as a plus for the Incyte Corp. stock. On the other hand our users think that "Customer and product portfolio" could be a problem in the future.
Pros and Cons of Incyte Corp. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Incyte Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Incyte Corp. | 0.820% | -2.680% | -7.597% | -27.514% | -14.892% | -31.813% | -27.098% |
Exact Sciences | 1.920% | -3.932% | -8.688% | -3.222% | -19.787% | -52.283% | -37.134% |
Regeneron Pharmaceuticals Inc. | -0.600% | -1.902% | -7.281% | 17.050% | 3.473% | 99.083% | 169.102% |
Amgen Inc. | 0.700% | -0.040% | -3.314% | 16.613% | -3.166% | 19.371% | 55.714% |
Comments
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for INCY provided by MarketBeat
Incyte Co. (NASDAQ: INCY) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $81.00 price target on the stock.
Show more
Ratings data for INCY provided by MarketBeat
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Citigroup Inc. from $82.00 to $81.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INCY provided by MarketBeat